<i>Alpha‐L‐fucosidase‐1</i> is a diagnostic marker that distinguishes mucoepidermoid carcinoma from squamous cell carcinoma

Ishida, Shoko; Kayamori, Kou; Sakamoto, Kei; Yukimori, Akane; Kugimoto, Takuma; Harada, Hiroyuki; Ikeda, Tohru

doi:10.1111/pin.12764

Cited by 8 publications

(8 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TP53 was mutated in 20.8% of the present MEC cases and this mutation frequency is comparable with previous studies (14.9–42.1%) 19,20,40,41 . TP53 mutations, which were detected more frequently in CRTC1/3–MAML2 fusion‐negative cases, were not associated with any clinicopathological factors and failed to show prognostic impact on DFS or OS.…”

Section: Discussionsupporting

confidence: 92%

Clinicopathological significance of EGFR pathway gene mutations and CRTC1/3–MAML2 fusions in salivary gland mucoepidermoid carcinoma

et al. 2020

View full text Add to dashboard Cite

Aims Mucoepidermoid carcinoma (MEC) is one of the most common salivary gland carcinomas. Epidermal growth factor receptor (EGFR) signalling pathway gene mutations are important in predicting a patient’s prognosis, selecting molecularly targeted drugs and estimating the efficacy of a molecular therapy. However, their significance in MEC have been poorly clarified. CRTC1/3–MAML2 fusions are specific to MEC and may be associated with favourable characteristics in these patients. Methods and results We looked for CRTC1/3–MAML2 fusions and gene alterations in the EGFR, RAS family (KRAS, HRAS and NRAS), PIK3CA, BRAF and AKT1 in 101 MEC cases. We also examined mutations in TP53. CRTC1/3–MAML2 fusions were found in 62.4% of the cases. KRAS, HRAS and PIK3CA mutations were detected in 6.9%, 2.0% and 6.9%, respectively, but other EGFR pathway genes were not mutated. In total, gene mutations (RAS/PIK3CA) in the EGFR pathway were detected in 14.9% of the cases. TP53 mutations were found in 20.8%. CRTC1/3–MAML2 fusions were associated with a better prognosis and RAS/PIK3CA mutations a worse prognosis of the patients, respectively, and both were selected as independent prognostic factors for the overall survival of the patients. TP53 mutations had no prognostic impact. CRTC1/3–MAML2 fusion‐positive rates were inversely associated with the patients’ age and the fusions were found in 82% of patients aged < 30 years. Conclusions RAS/PIK3CA mutations were frequently detected, and may be a biomarker for a poorer prognosis in MEC patients. CTRC1/3–MAML2 fusions were positive in most of the young MEC patients.

show abstract

Section: Discussionsupporting

confidence: 92%

Clinicopathological significance of EGFR pathway gene mutations and CRTC1/3–MAML2 fusions in salivary gland mucoepidermoid carcinoma

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In age-related macular degeneration patients, serum CD146 level was significantly higher than in the controls [47]. Alpha-L-fucosidase-1 (FUCA1), the enzyme that removes terminal α-L-fucose residues from glycoproteins, is downregulated in some high malignancy cancers [48]. Moreover, FUCA1 was shown to decrease the invasion capability of HuH28 cells by downregulating MMP-2 and MMP-9 [49].…”

Section: Prm Validationmentioning

confidence: 99%

Differential urine proteome analysis of a bovine IRBP induced uveitis rat model by discovery and parallel reaction monitoring proteomics

Qin

Wang

et al. 2019

Preprint

View full text Add to dashboard Cite

Uveitis, a group of intraocular inflammatory diseases, is one of the major causes of severe visual impairment among working age population. Urine is a promising resource for biomarker research, which could sensitively reflect the changes of the body. This study was designed to explore urinary protein biomarkers for diagnosis and/or monitoring of uveitis. Experimental autoimmune uveitis (EAU) rat model induced by bovine interphotoreceptor retinoid-binding protein (IRBP) was used to mimic the uveitis. In the discovery phase, urine samples from EAU and control rats were analyzed by data independent acquisition (DIA) approach combined with high-resolution mass spectrometry. Overall, 704 high confidential proteins were identified, of which 100 were differentially expressed (37, 33, 37, and 44 on day 5, 8, 12, and 16, respectively, after bovine IRBP immunization) (1.5-fold change, P<0.05). Gene Ontology analysis of the dysregulated proteins showed that chronic inflammatory response, neutrophil aggregation and immune system processes were significantly enriched. Finally, parallel reaction monitoring (PRM) approach was used for further validation. A total of 12 urinary proteins (MMP8, NGAL, HPT, UROM, RISC, A1AG, TTHY, KNT1, C9, PTER, CBG, and FUCA1) changed significantly, even when there is no clinical manifestations and histopathological ocular damages in the EAU rats. Our findings represent the first step towards urinary protein diagnostic biomarkers for uveitis. Biological Significance:This is the first study investigating urinary protein candidate biomarkers for uveitis using data independent acquisition (DIA) combined with parallel reaction monitoring (PRM) in experimental autoimmune uveitis (EAU) rats. The results revealed that urine is a promising resource for early diagnostics of uveitis. Further research including clinical urine samples is needed to determine the sensitivity and specificity of these candidate biomarkers for uveitis.

show abstract

“…AFU containing two isoforms, AFU1 and AFU2, is an enzyme that is capable of clearing the terminal α-l-fucose residues from glycoproteins ( 4 , 5 ). AFU1 and AFU2 are encoded by FUCA1 gene and FUCA2 gene, respectively.…”

Section: Introductionmentioning

confidence: 99%

Alpha-L-Fucosidase Has Diagnostic Value in Prostate Cancer With “Gray-Zone PSA” and Inhibits Cancer Progression via Regulating Glycosylation

et al. 2021

View full text Add to dashboard Cite

BackgroundThis study aimed to explore the diagnostic value of alpha-l-fucosidase (AFU) in prostate cancer (PCa) patients with “gray-zone PSA” and to investigate the correlation between AFU expression and clinicopathological characteristics of PCa patients.MethodsThe level of AFU and other necessary clinicopathological variables of patients were retrieved from electronic medical records. The transcriptome profiling and clinical information of PCa patients were obtained from The Cancer Genome Atlas (TCGA) database. The protein level of AFU in tissue was assessed by immunohistochemistry (IHC). All the data were processed by appropriate analysis methods. The p-value of <0.05 was considered statistically significant.ResultsAFU showed ideal diagnostic value for PCa with prostate-specific antigen (PSA) levels ranging from 4 to 10 ng/ml, and its optimal cutoffs were 19.5 U/L. Beyond this, low AFU expression was associated with high pathological grade, T stage and N stage, more postoperative residual tumors, and poor primary therapy outcome, as well as shorter progression-free interval. The Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis illustrated that FUCA1/FUCA2 exerted tumor-suppressive function by regulating the glycosylation.ConclusionsAFU (<19.5 U/L) could effectively distinguish the PCa from the patients with “gray-zone PSA”, and low expression of AFU was an independent unfavorable predictor for the clinicopathological characteristics of PCa patients.

show abstract

Alpha‐L‐fucosidase‐1 is a diagnostic marker that distinguishes mucoepidermoid carcinoma from squamous cell carcinoma

Cited by 8 publications

References 24 publications

Clinicopathological significance of EGFR pathway gene mutations and CRTC1/3–MAML2 fusions in salivary gland mucoepidermoid carcinoma

Clinicopathological significance of EGFR pathway gene mutations and CRTC1/3–MAML2 fusions in salivary gland mucoepidermoid carcinoma

Differential urine proteome analysis of a bovine IRBP induced uveitis rat model by discovery and parallel reaction monitoring proteomics

Alpha-L-Fucosidase Has Diagnostic Value in Prostate Cancer With “Gray-Zone PSA” and Inhibits Cancer Progression via Regulating Glycosylation

Contact Info

Product

Resources

About